STOCK TITAN

Meiwu Technology (NASDAQ: WNW) sells 25M shares in $15.65M PIPE

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Meiwu Technology Company Limited entered into a securities purchase agreement for a private PIPE financing, issuing 25,000,000 ordinary shares at $0.626 per share for gross proceeds of approximately $15,650,000. The deal closed on May 8, 2026, after which 26,330,471 ordinary shares were issued and outstanding.

The company agreed to 12‑month restrictions on new equity issuance, registration filings and variable rate transactions without majority purchaser consent, while purchasers accepted a 12‑month lock-up on sales. Meiwu plans to use most of the net proceeds to build an AI‑ and data‑driven skincare management platform, expand its workforce, and fund related digital infrastructure and commercialization, alongside general corporate purposes.

The filing highlights new risk factors, including uncertainty around developing and monetizing the platform, evolving AI, healthcare and consumer-protection regulation, intense competition for qualified technical staff, and heightened data privacy and cybersecurity compliance obligations, particularly under Chinese laws and the EU’s GDPR.

Positive

  • Raised $15.65 million in new equity capital, providing meaningful funding to develop an AI‑driven skincare management platform, expand headcount and support digital infrastructure and commercialization initiatives.

Negative

  • Substantial equity issuance creates immediate dilution, with 25,000,000 new shares issued relative to 26,330,471 shares outstanding post‑closing, while the new AI skincare platform is still early‑stage and faces significant execution and regulatory risks.

Insights

Meiwu raises fresh equity via a large PIPE to fund an AI skincare pivot, with tight issuance limits and notable execution risks.

Meiwu Technology completed a private PIPE, issuing 25,000,000 ordinary shares at $0.626 for gross proceeds of $15,650,000, bringing total shares to 26,330,471. This materially reshapes the capital structure and provides meaningful cash to support a shift toward an AI‑based skincare management platform and related digital infrastructure.

In exchange, the company accepted 12‑month constraints on additional share issuance, registration and variable rate transactions, while investors agreed to a 12‑month lock-up. These terms temper near‑term financing flexibility but may reduce overhang from rapid follow‑on deals or immediate resale. Economically, the transaction balances capital needs against dilution and structural limitations.

The new strategy carries significant execution and regulatory risk. The company calls out early‑stage technology development, heavy spending needs, uncertain commercialization, complex AI and health‑adjacent regulation across China, the U.S. and EU, and strict data privacy and cybersecurity regimes such as GDPR. Future disclosures in company filings will be important to track spending progress, regulatory interactions and any traction of the skincare platform initiative.

PIPE shares issued 25,000,000 shares Ordinary shares sold in May 2026 private offering
PIPE share price $0.626 per share Purchase price for ordinary shares in the PIPE
Gross proceeds $15,650,000 Subscription Amount from the PIPE before expenses
Shares outstanding post‑deal 26,330,471 shares Ordinary shares issued and outstanding after closing
Lock-up period 12 months Purchasers restricted from selling Meiwu securities
Issuance and variable-rate restriction 12 months Limits on new issuances and Variable Rate Transactions
PIPE financial
"The Ordinary Shares issued in this PIPE have not been registered under the Securities Act of 1933"
A "pipe" is a planned series of financial transactions or projects that companies intend to carry out over time, often involving the raising of funds or development of new assets. It matters to investors because it provides a clear picture of a company's future growth plans and potential revenue, helping them assess the company's upcoming opportunities and overall stability. Think of it as a detailed roadmap guiding a company's future steps.
Variable Rate Transaction financial
"not to enter into or effect any Variable Rate Transaction (as defined in the Securities Purchase Agreement)"
Regulation S regulatory
"issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation S promulgated thereunder"
Regulation S is a set of rules that allows companies to sell securities (like shares or bonds) to investors outside the United States without having to follow all U.S. securities laws. It matters because it makes it easier for companies to raise money from international investors while still complying with U.S. regulations.
GDPR regulatory
"European Union’s General Data Protection Regulation (“GDPR”)"
General Data Protection Regulation is a law that sets rules for how organizations must collect, store and use personal data about people, and gives individuals rights over that data. It matters to investors because noncompliance can lead to large fines, higher operating costs and damaged reputation, while strong compliance can be a competitive advantage—think of it as a strict safety code for handling customer information.
forward-looking statements regulatory
"CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Securities Purchase Agreement financial
"entered into a securities purchase agreement (the “Securities Purchase Agreement”)"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of May 2026

 

Commission File Number: 001-39803

 

Meiwu Technology Company Limited

(Translation of registrant’s name into English)

 

Unit 304-3, No.19, Wanghai Road, Siming District

Xiamane, Fujian, People’s Republic of China

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒   Form 40-F ☐

 

 

 

 

 

 

Entry into Material Definitive Agreement

 

On May 5, 2026, Meiwu Technology Company Limited (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain purchasers (the “Purchasers”), pursuant to which the Company agreed to sell and issue an aggregate of 25,000,000 ordinary shares of the Company (the “Ordinary Shares”), with no par value, at a purchase price of $0.626 per share in a private transaction (the “Offering”).

 

The gross proceeds to the Company from the Offering were approximately $15,650,000 (the “Subscription Amount”), before deducting other offering expenses payable by the Company. The offering was closed on May 8, 2026. Immediately following the closing of the Offering, the Company has 26,330,471 Ordinary Shares are issued and outstanding.

 

Pursuant to the Securities Purchase Agreement, the Company has agreed not to (i) issue or enter into an agreement to issue any Ordinary Shares or Ordinary Share Equivalents (as defined in the Securities Purchase Agreement), or (ii) file any registration statement or amendment or supplement thereto, subject to certain exceptions, for a period beginning on the date of the Securities Purchase Agreement and ending on the twelve (12) months following the closing date, without written consent by a majority of the Purchasers where the consenting Purchases have more than 51% of the Subscription Amounts. The Company has also agreed not to enter into or effect any Variable Rate Transaction (as defined in the Securities Purchase Agreement) beginning on the date of the Securities Purchase Agreement and ending on the twelve (12) months following the closing date.

 

The Ordinary Shares issued in this PIPE have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation S promulgated thereunder.

 

In connection with the Securities Purchase Agreement, each of the Purchasers also entered into a lock-up agreement (the “Lock-Up Agreement”), pursuant to which, they agreed not to sell, transfer or otherwise dispose of any Ordinary Shares or similar securities or any securities convertible into or exchangeable or exercisable for our ordinary shares, for a period of twelve (12) months following the date thereof.

 

This Report on Form 6-K shall not constitute an offer to sell or the solicitation to buy nor shall there be any sale of the shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

The foregoing description of the Securities Purchase Agreement and the Lock-Up Agreement, is not complete, and is qualified in its entirety by reference to the full text of such document, copies of the forms of which are attached hereto as Exhibits 10.1 and 10.2.

 

Use of Proceeds and Business Initiatives

 

The Company intends to use the net proceeds from the Offering primarily to support the development of a skincare management platform utilizing AI and data-analysis technologies, and related digital infrastructure, as well as for general corporate purposes and working capital.

 

2

 

 

In connection with this initiative, the Company plans to expand its workforce across different departments, including product development, research and development, and commercialization. The Company expects the proposed platform to support customer engagement, skincare management services, and the enhancement of its existing skincare product and training business.

 

A substantial portion of the proceeds is expected to be used for personnel recruitment, platform and application development, infrastructure and operational support, and commercialization activities associated with the Company’s technology initiatives.

 

Risk Factors

 

Risks related to the Company’s proposed skincare management platform

 

The Company’s planned skincare management platform is in an early stage of development, and the Company may not successfully develop or commercialize the platform.

 

The Company is in the process of expanding beyond its existing skincare products and training services business to develop a skincare management platform utilizing AI and data-analysis technologies. The development and commercialization of such technologies involve significant risks, uncertainties, technical challenges, and substantial expenditures.

 

The Company’s proposed platform may require significant investments in personnel recruitment, software development, infrastructure, data management, regulatory compliance, and commercialization activities. There can be no assurance that the Company will successfully develop, deploy, market, or monetize the platform on a timely basis, or at all. If the Company is unable to execute its technology strategy effectively, its business, financial condition, and results of operations could be materially adversely affected.

 

The Company’s AI-related services may be subject to evolving laws and regulations relating to healthcare, medical devices, consumer protection, and artificial intelligence technologies.

 

Certain functionalities contemplated for the Company’s proposed platform may involve AI-assisted skin analysis, skincare recommendations, or related consumer-facing features. Regulatory authorities in various jurisdictions, including China, the United States, and the European Union, may interpret certain AI-enabled analytical or recommendation functions as implicating medical, healthcare, diagnostic, medical-device, or consumer-protection regulations.

 

The Company intends to position its services as consumer skincare and lifestyle-related services rather than medical diagnosis or treatment services. However, the regulatory framework governing AI technologies, digital health applications, and related consumer services remains uncertain and rapidly evolving. Changes in laws, regulations, regulatory interpretations, or enforcement practices could subject the Company to additional licensing requirements, operational restrictions, compliance burdens, investigations, penalties, or other liabilities.

 

In addition, if users, regulators, or third parties perceive the Company’s services as providing medical advice or diagnostic functions without appropriate approvals or qualifications, the Company’s reputation, operations, and business prospects could be adversely affected.

 

The Company’s growth strategy depends on its ability to recruit and retain qualified personnel.

 

The Company expects to use a substantial portion of the proceeds from the Offering to recruit personnel across product development, research and development, commercialization, and related functions. Competition for experienced AI engineers, software developers, data specialists, and other qualified personnel is intense.

 

The Company’s future success will depend in significant part on its ability to attract, integrate, manage, and retain qualified employees and consultants. If the Company is unable to recruit or retain personnel with the necessary technical and operational expertise, its ability to execute its growth strategy may be materially adversely affected.

 

The Company’s business may be adversely affected by risks relating to data privacy, cybersecurity, and the handling of sensitive user information.

 

The Company expects that its proposed platform may process user data, including facial images, skincare-related information, behavioral data, and other potentially sensitive personal information. The collection, storage, processing, transfer, and protection of such information are subject to increasingly complex and evolving laws and regulations in multiple jurisdictions, including China’s data protection and cybersecurity laws and the European Union’s General Data Protection Regulation (“GDPR”).

 

Any failure to comply with applicable data privacy, cybersecurity, or data localization requirements could result in investigations, regulatory actions, fines, litigation, reputational harm, operational disruptions, or restrictions on the Company’s business activities.

 

In addition, cyberattacks, unauthorized access, data breaches, employee misconduct, software vulnerabilities, or other security incidents could compromise sensitive user information or disrupt the Company’s operations. The Company may also incur significant costs in responding to security incidents, implementing remediation measures, and maintaining compliance systems.

 

3

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Current Report on Form 6-K, including the sections entitled “Use of Proceeds and Business Initiatives,” and “Risk Factors,” contains express or implied forward-looking statements that are based on our management’s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Current Report on Form 6-K include, but are not limited to, statements about:

 

  the implementation of our strategic plans for our business;
  our financial performance;
  developments relating to our competitors and our industry, including the impact of government regulation;
  estimates of our expenses, future revenues, capital requirements and our needs for additional financing; and
  other risks and uncertainties, including those listed under the captions “Use of Proceeds and Business Initiatives,” and “Risk Factors”.

 

In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” “could,” “project,” “intend,” “will,” “will be,” “would,” or the negative of these terms or other comparable terminology and expressions. However, this is not an exclusive way of identifying such statements. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section entitled “Risk Factors” and elsewhere in this Current Report on Form 6-K. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Current Report on Form 6-K and the documents that we reference in this Current Report on Form 6-K and have filed with the Securities and Exchange Commission (“SEC”) as exhibits hereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.

 

The forward-looking statements in this Current Report on Form 6-K represent our views as of the date of this Current Report on Form 6-K. We anticipate that subsequent events and developments will cause our views to change. Except as expressly required under federal securities laws and the rules and regulations of the SEC, we do not undertake any obligation to update any forward-looking statements to reflect events or circumstances arising after the date of this Current Report on Form 6-K, whether as a result of new information or future events or otherwise. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Current Report on Form 6-K. You should not place undue reliance on the forward-looking statements included in this Current Report on Form 6-K. All forward-looking statements attributable to use are expressly qualified by these cautionary statements.

 

Exhibits

 

Exhibit No.   Description
10.1   Form of Securities Purchase Agreement, dated May 5, 2026
10.2   Form of Lock-Up agreement, dated May 5, 2026

 

4

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: May 8, 2026

 

  Meiwu Technology Company Limited
     
  By: /s/ Handy Wijaya
  Name: Handy Wijaya
  Title: Co-Chief Executive Officer

 

5

 

FAQ

What capital did Meiwu Technology (WNW) raise in the May 2026 PIPE?

Meiwu Technology raised approximately $15.65 million in a private PIPE by issuing 25,000,000 ordinary shares at $0.626 per share. The financing closed on May 8, 2026, and materially increased the company’s total shares outstanding.

How many Meiwu Technology (WNW) shares are outstanding after the PIPE?

Immediately after the PIPE closing, Meiwu Technology had 26,330,471 ordinary shares issued and outstanding. This figure reflects the addition of 25,000,000 new shares sold in the private offering completed on May 8, 2026.

How will Meiwu Technology (WNW) use the PIPE proceeds?

Meiwu Technology plans to use net proceeds primarily to build an AI- and data-driven skincare management platform, expand its workforce, and fund platform and application development, infrastructure, operational support, and commercialization, along with general corporate purposes and working capital.

What lock-up and issuance restrictions apply after Meiwu Technology’s PIPE?

Purchasers agreed to a 12‑month lock-up on selling or transferring Meiwu shares and similar securities. The company also agreed to a 12‑month restriction on most new share issuances, registration filings and variable rate transactions without consent from purchasers holding over 51% of subscription amounts.

What key risks does Meiwu Technology (WNW) highlight for its AI skincare platform?

Meiwu cites risks from early-stage development, significant required investment, uncertain commercialization, evolving AI, healthcare and consumer-protection regulation, intense competition for technical talent, and strict data privacy and cybersecurity rules in China and under the EU’s GDPR.

Under what exemptions were Meiwu Technology (WNW) PIPE shares issued?

The PIPE ordinary shares were issued without SEC registration, relying on exemptions under Section 4(a)(2) of the Securities Act and/or Regulation S. This structure limits resale to transactions that comply with applicable U.S. and international securities regulations.

Filing Exhibits & Attachments

2 documents